Simona Lamba

University of Turin — Italy

Medicine · Health Sciences

32h-index7.3kcitations145works4.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(63), Genetic factors in colorectal cancer(32), Cancer Genomics and Diagnostics(29), Lung Cancer Treatments and Mutations(18), Ferroptosis and cancer prognosis(14)

Publications145 total

ROLE OF PCR IN IDENTIFICATION OF HELMINTH PARASITES
2025Open Access
MOLECULAR INTERACTIONS BETWEEN CHICKENS AND NEMATODE PARASITES: INVASION MECHANISMS, IMMUNE RESPONSES, AND IMPLICATIONS FOR POULTRY HEALTH
2025Open Access
Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models
Cancer Cell·2025· 10 citedOpen Access
Abstract 6169: Immunogenic cell death mediates the anticancer efficacy of high dose vitamin C
Cancer Research·2025
Abstract 4190: CRISPR-CAS9 library screening identifies novel vulnerabilities in CRC drug-tolerant persister cells
Cancer Research·2025
DNA demethylation triggers cell free DNA release in colorectal cancer cells
Genome Medicine·2024· 6 citedOpen Access
Preclinical efficacy of carfilzomib in <i>BRAF</i> ‐mutant colorectal cancer models
Molecular Oncology·2024· 5 citedOpen Access
Non-canonical antigens are the largest fraction of peptides presented by MHC class I in mismatch repair deficient murine colorectal cancer
Genome Medicine·2024· 15 citedOpen Access
Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells
Cell Reports Medicine·2024· 12 citedOpen Access
Abstract B005: Tolerance to colibactin correlates with response to chemotherapeutic agents in colorectal cancer
Cancer Research·2024
Author response for "Preclinical efficacy of carfilzomib in &lt;i&gt;BRAF&lt;/i&gt;‐mutant colorectal cancer models"
2023
Author response for "Preclinical efficacy of carfilzomib in &lt;i&gt;BRAF&lt;/i&gt;‐mutant colorectal cancer models"
2023
2235P Chemotherapy priming leads to hypermutability and immune surveillance in colorectal cancer
Annals of Oncology·2023
18P Exposure of calreticulin is required for vitamin C immunomediated cancer surveillance
Annals of Oncology·2023Open Access
Dual <scp>VEGFA</scp>/<scp>BRAF</scp> targeting boosts <scp>PD</scp>‐1 blockade in melanoma through <scp>GM‐CSF</scp>‐mediated infiltration of <scp>M1</scp> macrophages
Molecular Oncology·2023· 8 citedOpen Access
Abstract 5900: Tolerance to colibactin correlates with response to chemotherapeutic agents in colorectal cancer
Cancer Research·2023· 1 cited
Supplementary Table 2 from EGFR Blockade Reverts Resistance to KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibition in Colorectal Cancer
2023Open Access
Supplementary Figure 2 from EGFR Blockade Reverts Resistance to KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibition in Colorectal Cancer
2023Open Access
Supplementary Table 3 from EGFR Blockade Reverts Resistance to KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibition in Colorectal Cancer
2023Open Access
Supplementary Figure 3 from EGFR Blockade Reverts Resistance to KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibition in Colorectal Cancer
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Alberto Bardelli(44), Federica Di Nicolantonio(32), Salvatore Siena(20), Andrea Sartore‐Bianchi(15), Sabrina Arena(13), Mariangela Russo(13), Giuseppe Rospo(11), Giorgio Corti(10), Giovanni Crisafulli(9), Alice Bartolini(9), Fonnet E. Bleeker(9), Benedetta Mussolin(8), Annalisa Lorenzato(8), Giulia Siravegna(7), Emanuele Valtorta(7), Silvia Marsoni(7), Giovanni Germano(7), Sieger Leenstra(7), Aldo Scarpa(7), Milo Frattini(6)